Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ZURA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — The Chief Financial Officer was separated from the company on April 20, 2026, though the company explicitly states it was not related to financial or operational disagreements.
Zura Bio CFO Eric Hyllengren separated; VP Finance Marlyn Mathew promoted to principal financial officer
Filed April 23, 2026 · Period ending April 20, 2026 · ~1 min read
Key Changes
-
high
CFO Eric Hyllengren was separated from the company on April 20, 2026. The company states the departure was not related to financial results, operations, or any disagreements about reporting practices.
Item 5.02 verify on EDGAR → -
high
Marlyn Mathew, VP of Finance and Accounting since June 2022, was immediately appointed principal financial and accounting officer with annual salary increased to $366,415.
Item 5.02 verify on EDGAR → -
medium
Mathew brings relevant experience as Controller at Immunovant (2019-2022) and has been with Zura Bio for nearly four years, suggesting continuity in financial leadership.
Item 5.02 verify on EDGAR → -
medium
Hyllengren will receive three months base salary severance plus up to six months of COBRA premium reimbursement under the separation agreement signed April 21, 2026.
Item 5.02, Exhibit 10.1 verify on EDGAR →
Summary
Zura Bio disclosed an abrupt CFO transition on April 20, 2026. Eric Hyllengren, who served as Chief Financial Officer and principal accounting officer, was separated from the company and immediately replaced by Marlyn Mathew, the company's VP of Finance and Accounting since June 2022.
The company emphasized that Hyllengren's departure was unrelated to financial results or any disagreements about operations or reporting practices—standard boilerplate language that aims to reassure investors but doesn't explain the actual reason for the separation. For retail shareholders, CFO departures warrant attention even when characterized as amicable.
Mathew's promotion from within suggests some continuity, and her four-year tenure at Zura Bio plus prior controller experience at Immunovant indicates she's familiar with the company's financials. However, the modest severance package ($366,415, three months salary) is relatively light for an executive departure, which could signal either a mutual agreement or performance-related issues. Investors should watch the next quarterly earnings call and 10-Q filing closely. Management commentary about the transition and any changes in financial reporting quality or tone will reveal whether this was truly routine or signals deeper operational challenges. The company's ability to maintain financial controls and reporting timeliness under new leadership will be the key test.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Ms. Mathew, 42, serves as the Company’s Vice President, Finance and Accounting, a role she has held since June 2022. Prior to joining the Company, Ms. Mathew was Controller at Immunovant from 2019 to May 2022, having previously served as Assistant Controller from 2018 to 2019.
Marlyn Mathew has been with Zura Bio as VP of Finance and Accounting since June 2022. Before that, she was Controller at Immunovant from 2019 to May 2022 and Assistant Controller from 2018 to 2019, bringing relevant financial leadership experience.
Event · Item 9.01 — Financial Statements and Exhibits
Zura Bio disclosed a separation agreement with Eric Hyllengren, effective April 21, 2026.
Added in current filing · verify on EDGAR →
Separation Agreement, by and between the Company and Eric Hyllengren, signed April 21, 2026
Zura Bio entered into a separation agreement with Eric Hyllengren on April 21, 2026.Investors should review the full exhibit to understand any severance payments, equity treatment, or post-employment restrictions.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify